Can We Bring Drug Discovery Back to the Future?
On Founding ReSync Bio
The pharmaceutical industry has seen a surge in computational technologies and AI in recent decades, promising to revolutionize drug discovery. Yet, despite these advancements, the process of bringing new drugs to market remains slow (7+ years from Target ID to IND) and increasingly expensive—with $1-2B being nominal discovery and trial costs.
This trend, known as Eroom's Law, sees drug development costs doubling almost every decade. The dichotomy between excitement for AI and lackluster growth in drug approvals highlights a crucial gap between computational breakthroughs and their practical implementation in drug development. AI’s impact on overall R&D productivity is still to be proven.
The experimental side of drug discovery has also seen process change. A major trend in drug development has been the utilization of contract research organizations that can reduce the cost and parallelize the processes of R&D. The American pharmaceutical market’s reliance on these contractors has been made clear by concern around BIOSECURE Act, which threatens to limit access to some of the largest international CROs. While outsourced scientific work can stretch financing further than costly in-house labs, virtual drug discovery comes with its own challenges, especially around the “coordination headwind” of people and data. When trying to standardize request and fulfillment across 5+ contractors in 3 global time zones, poor organization can compound into massive issues for a drug program.
In our team’s and customers’ experience, this missed information can lead to massive losses: weeks wasted re-synthesizing compounds, missed patent filing windows, and faulty assays spoiling training data. Many groups we speak to struggle to manage this process manually over email, spreadsheets, and a team of unhappy scientists-turned-project-managers.
Bridging the Gap
There's a pressing need for solutions that effectively bridge the gap between modern computational methods and real-world drug development. In the past decade, we’ve seen the major players in AI-driven drug discovery realize this and build out the necessary engineering and infrastructure teams in-house. To truly accelerate the global development of cures, however, we need to build common platforms that span the industry.
At ReSync, we’re aiming to build the bridge: a singular platform to integrate virtual and computational drug discovery seamlessly with experimental data and workflows.
Our Vision for ReSync
We founded ReSync with a simple mission: accelerate drug discovery programs across the industry. Our goals are to empower pharmaceutical and biotechnology companies to:
Make efficient decisions in the hybrid and virtual lab environment: Onboarding a new CRO shouldn’t require weeks of process definition and back-and-forth. ReSync natively tracks requests and fulfillment, and can provide templates for a variety of assay data types.
Adopt new technologies without overhead: We aim to supercharge biotech teams by providing a centralized data solution - allowing one-click integrations of homegrown models and benchmarks of open source and academic research.
Enhance collaboration and data security: ReSync’s platform is designed to facilitate seamless collaboration between internal teams and external partners while maintaining strict control over data access and intellectual property protection.
The drug industry faces a grand challenge in improving R&D productivity. At ReSync, we aspire to do our part in providing the best discovery platform for players of any size - from startup to pharma - so they can dedicate themselves to life-saving science. Our team is made up of brilliant scientists and engineers who are passionate about our mission. If this sounds exciting to you, check out our open roles here.
Want to start integrating ReSync into your lab or company? Click below for expedited access to ReSync’s platform. To learn more reach us at hello@resync.bio and find more information on our website.
Other reads we’ve enjoyed recently:
